Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

PET Could Outshine Other Modalities for CAD

While there has been a movement toward the advocacy of the use of PET imaging for the detection of coronary artery disease (CAD) due to higher resolution and new promising tracers, but whether the modality will trump CT or SPECT as the gold standards remains to be seen.

Tipping the Scales: Molecular Imaging & The Obese Patient

The ripple effect of the obesity epidemic is felt through the entire healthcare system, and for molecular imaging, it affects safety, efficiency and diagnostic quality.

Florbetapir: Alzheimer’s Imaging Inches Into Practice

The practice management considerations, as well as uncertainty about the meaning of a beta-amyloid, scan are impacting early adopters.

Value-based Purchasing: What It Means for Performance Evaluation

Now that the fee-for-service reimbursement model may be coming to an end, radiology providers will have to adjust pracice to survive (and succeed) in a value-based environment.

A Merger in Maine

Two large cardiology practices in Maine merged with an integrated delivery network. The integration demanded a complete overhaul of governance, IT considerations and molecular imaging workflow.

Theranostics Dissected

Recent developments in theranostics could usher in an era that helps drive personalized medicine from research to reality.

PET tracer predicts resistance to hormone therapy for breast cancer

18F-labeled fluoromisonidazole (18F-FMISO) PET/CT can be used during breast cancer treatment planning to predict primary endocrine resistance in estrogen receptor (ER)-positive cancers, according to a study published Feb. 11 in the Journal of Nuclear Medicine.

Banner Health secures $16.3M to launch imaging center

The Banner Alzheimer’s Institute is going to build an imaging center for the  research and treatment of Alzheimer’s disease, as well as heart disease and cancer, with $16.3 million in federal grants and donations.